Calix Ltd (ASX: CXL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Calix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Calix Ltd (ASX: CXL)
Latest News
Share Gainers
Why A2 Milk, Calix, CSL, and Ioneer shares are charging higher today
Technology Shares
Up 161% in 3 weeks, why is this surging ASX tech stock tumbling today?
Technology Shares
Why is this ASX tech stock jumping 14% on Friday?
Resources Shares
Rio Tinto milestone sends shares in resources tech stock higher
Materials Shares
Pilbara Minerals shares charge higher on 'game-changer' news
Share Fallers
Why ANZ, Calix, Paradigm, and Platinum shares are tumbling today
Technology Shares
Guess which ASX 300 stock is rocketing 15% today
ASX Share Market News
Why Calix, Collins Foods, Myer, and Patriot Battery Metals shares are charging higher
Technology Shares
Guess which ASX tech stock could double in value
ASX Share Market News
Insiders are buying Mesoblast and these ASX shares
Share Gainers
Why Calix, Genex, Life360, and Spartan Resources shares are rising
Technology Shares
Guess which ASX tech stock is jumping 15% today
Frequently Asked Questions
-
Calix Ltd does not pay shareholder dividends at this time.
-
Calix listed on the ASX on 20 July 2018.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Sep 2005 | $0.0150 | 100.00% | Final | 07 Oct 2005 |
CXL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Calix Ltd
Calix Ltd (ASX: CXL) is an Australian technology company. It has developed a patented, platform technology that essentially involves grinding minerals to between one-hundredth and one-thousandth of a millimetre in size, and then "flash" heating them in a reactor. As trapped gases in the minerals are released, they create highly porous honeycomb-like structures with similar properties to nanomaterials, but without the associated safety issues and costs. Calix's technology also allows for the separation of carbon dioxide, making it attractive to industries and companies looking to reduce carbon emissions.
Calix's technology is being used globally across many industries and sectors. These include advanced battery development, water and wastewater treatment, sustainable food, and biotechnology. The company has operations in Australia, New Zealand, Asia, Europe, and the United States.
CXL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Oct 2026 | $0.21 | $-0.01 | -4.55% | 625,035 | $0.22 | $0.22 | $0.20 |
| 15 Oct 2026 | $0.22 | $-0.01 | -4.26% | 181,187 | $0.24 | $0.24 | $0.21 |
| 14 Oct 2026 | $0.24 | $0.02 | 9.52% | 340,539 | $0.21 | $0.24 | $0.21 |
| 13 Oct 2026 | $0.21 | $-0.02 | -8.70% | 130,200 | $0.23 | $0.23 | $0.21 |
| 12 Oct 2026 | $0.23 | $0.01 | 4.55% | 65,703 | $0.23 | $0.23 | $0.22 |
| 09 Oct 2026 | $0.22 | $-0.01 | -4.44% | 75,203 | $0.23 | $0.23 | $0.22 |
| 08 Oct 2026 | $0.23 | $-0.01 | -4.26% | 193,762 | $0.24 | $0.24 | $0.22 |
| 07 Oct 2026 | $0.24 | $0.00 | 0.00% | 179,931 | $0.23 | $0.24 | $0.22 |
| 06 Oct 2026 | $0.23 | $0.01 | 4.44% | 36,166 | $0.23 | $0.23 | $0.22 |
| 05 Oct 2026 | $0.23 | $0.00 | 0.00% | 189,628 | $0.23 | $0.24 | $0.23 |
| 02 Oct 2026 | $0.23 | $-0.01 | -4.26% | 330,568 | $0.24 | $0.24 | $0.22 |
| 01 Oct 2026 | $0.24 | $-0.01 | -4.17% | 189,218 | $0.25 | $0.25 | $0.24 |
| 30 Sep 2026 | $0.24 | $0.01 | 4.35% | 88,784 | $0.24 | $0.24 | $0.24 |
| 29 Sep 2026 | $0.23 | $0.00 | 0.00% | 280,320 | $0.25 | $0.25 | $0.23 |
| 28 Sep 2026 | $0.23 | $-0.01 | -4.17% | 446,331 | $0.24 | $0.25 | $0.23 |
| 25 Sep 2026 | $0.24 | $0.01 | 4.26% | 152,414 | $0.25 | $0.25 | $0.23 |
| 24 Sep 2026 | $0.24 | $-0.01 | -4.08% | 153,531 | $0.25 | $0.25 | $0.24 |
| 23 Sep 2026 | $0.25 | $-0.01 | -3.92% | 59,747 | $0.26 | $0.26 | $0.24 |
| 22 Sep 2026 | $0.26 | $0.00 | 0.00% | 131,042 | $0.26 | $0.26 | $0.24 |
| 21 Sep 2026 | $0.26 | $0.02 | 8.51% | 170,403 | $0.26 | $0.26 | $0.24 |
| 18 Sep 2026 | $0.24 | $0.01 | 4.44% | 269,637 | $0.24 | $0.26 | $0.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Dec 2025 | Catriona Deans | Issued | 179,167 | $107,500 |
Director remuneration.
|
| 05 Dec 2025 | Helen Fisher | Issued | 112,500 | $67,500 |
Director remuneration.
|
| 05 Dec 2025 | Sarah Ryan | Issued | 112,500 | $67,500 |
Director remuneration.
|
| 05 Dec 2025 | Peter Dixon | Issued | 112,500 | $67,500 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Catriona Alison Deans | Non-Executive DirectorNon-Executive Chairman | Mar 2023 |
Ms Deans has 25 years of experience building businesses involved in media, ecommerce, financial services and health, and across leadership roles as an executive, a director and in venture capital. Alison is currently the Chair of Cochlear, and a Non-Executive Director of Ramsay Health Care and Fitness Passport Pty Ltd. She is also on the Investment Committee of Main Sequence Ventures. Alison was previously on the boards of Westpac Banking Corporation, IAG (Insurance Australia Group Limited) and Deputy Group Pty Ltd. In her executive career, Alison was previously the first CEO of eBay Australia and New Zealand, CEO of eCorp Limited, (a publicly listed portfolio of digital businesses), CEO of Hoyts Cinemas, and CEO of netus Pty Ltd - a technology investment company acquired by Fairfax.
|
| Ms Helen E Fisher | Non-Executive Director | Sep 2020 |
Ms Fisher is a leader with a rare combination of financial expertise and knowledge and global networks in the Life Sciences sector. Helen is the founding CEO and Managing Director of Bio Capital Impact Fund (BCIF), and the Chair of the Victorian branch of AusBiotech. Helen was formerly a Non-Executive Director of Paradigm Biopharmaceuticals Ltd and a member of the American Chamber of Commerce in Australia Health Committee. Prior to establishing the BCIF, Helen was a partner of Deloitte and led Deloitte life sciences practice in Australia for 5 years, having had many years of experience in the life sciences and health care sector. She also specialised in the financial services sector, servicing banks and funds and has been involved in setting up a few international funds, as well as advised on a few M&A transactions. Helen has provided strategic tax advice to publicly listed and multinational companies and has experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP and supply chain management.
|
| Dr Philip (Phil) Hargraves Hodgson | Chief Executive OfficerManaging Director | Feb 2014 |
Dr Hodgson has a technical and commercial background from a career with Shell, where for over 14 years he developed depth of experience across all key sectors of the Downstream oil industry including refining and supply, marketing and sales, pricing strategy, risk management, corporate strategy and mergers and acquisitions. From 2007 to 2013, Phil ran his own consultancy providing project development, commercial and M&A, and management expertise to a few sectors including LNG, Biofuel, Clean Coal, Geothermal Energy, Building Products, Logistics and fast-moving consumer goods.
|
| Dr Sarah Elizabeth Ryan | Non-Executive Director | Jan 2024 |
Dr Ryan is an experienced non-executive director and former senior operational executive with global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a combination of technical expertise, commercial experience and a particular emphasis on innovation and technology enabled solutions, Sarah has led and helped to build organisations across the energy, natural resources, and infrastructure sectors. Sarah is currently a non-executive director of Viva Energy Group Limited, Aurizon Holdings Limited, Transurban Group and the Future Battery Industries Co-operative Research Centre. Until recently, Sarah was a non-executive director of Oz Minerals Limited and Woodside Energy Group Limited. Sarah is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.
|
| Mr Peter Matthew Francis Dixon | Non-Executive Director | Jan 2024 |
Mr Dixon has 25 years of experience across the legal, investment banking and funds management sectors. He brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Peter is currently Chief Strategy Officer for HPX Group and is a non-executive director at Johns Lyng Group Limited. His investment banking and legal experience include private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group General Counsel. Peter also spent time earlier in his career at Macquarie Group Limited in various roles across corporate strategy, investment management and corporate advisory.
|
| Mr Darren Charles | Chief Financial OfficerCompany Secretary |
-
|
|
| Darren Charles | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 39,762,961 | 18.41% |
| Citicorp Nominees Pty Limited | 17,246,790 | 7.99% |
| HSBC Custody Nominees (Australia) Limited | 12,750,087 | 5.91% |
| Nicholas Merriman | 8,108,286 | 3.75% |
| Thorney International Pty Ltd | 6,986,416 | 3.24% |
| Mr Paul Crowther | 5,150,000 | 2.38% |
| UBS Nominees Pty Ltd | 4,526,536 | 2.10% |
| Dr Mark Geoffrey Sceats | 3,701,268 | 1.71% |
| Mark Geoffrey Sceats <Sceats Superannuation Fund> | 2,847,344 | 1.32% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> | 2,605,377 | 1.21% |
| Pigeons Super Pty Limited <The Hodgson Family S/F A/C> | 2,461,597 | 1.14% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,446,777 | 1.13% |
| Phil Hodgson | 1,888,309 | 0.88% |
| Mr Samuel Thomas Grech | 1,800,050 | 0.83% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,719,280 | 0.80% |
| Mr Jacob Shields Ulrich | 1,703,133 | 0.79% |
| Jeneil Super Pty Ltd <Jeneil Super Fund A/C> | 1,266,388 | 0.59% |
| CY Capital Pty Ltd | 1,240,000 | 0.57% |
| Mr John Andrew Hamilton | 1,223,639 | 0.57% |
| Mr Timothy John Reed & Ms Karola Brent <The Private Fund S/F A/C> | 1,169,000 | 0.54% |